drug_type
RELEVANT_DRUG
intervention_type
Genetically modified cellular therapy (CAR-NK)
drug_description
Gene-modified, allogeneic cord blood–derived natural killer (NK) cells engineered with a TROP2-specific chimeric antigen receptor and transduced to express IL-15; administered intraperitoneally to target TROP2-positive tumors and enhance NK survival and persistence.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intraperitoneal
drug_mechanism_of_action
Allogeneic cord blood-derived NK cells engineered with a TROP2-specific chimeric antigen receptor and IL-15 expression. CAR recognition of TROP2 on tumor cells triggers NK activation and cytolytic killing (perforin/granzyme), while IL-15 supports NK survival, proliferation, and persistence; delivered intraperitoneally to target TROP2-positive tumors.
drug_name
TROP2-CAR-NK
nct_id_drug_ref
NCT05922930